Akoya Biosciences
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Spatial-biology tools for tissue analysis and biomarker research.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Acquired by Quanterix
On July 8, 2025, Quanterix completes its acquisition of Akoya Biosciences under an amended merger agreement announced April 29, issuing about 7.8 million Quanterix shares and paying about $20 million in cash to Akoya shareholders, creating an integrated biomarker platform spanning blood and tissue. Akoya executives are terminated as part of a cost-saving plan expected to incur $33 million in related expenses.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.